DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.
The San Diego-based company issued the bullish forecast on Monday alongside preliminary 2025 results that showed total revenue reached $4.66 billion, a 16% increase over the previous year.
Dexcom’s international business led the growth charge with an 18% jump, while domestic sales rose 11% to $892 million in the fourth quarter.
"We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance," said Jake Leach, who officially assumed the role of President and CEO on Jan. 1.
Leach highlighted the early success of the G7 15-Day system, which began shipping to U.S. pharmacies this month.
The new device offers 50% more wear time than the standard G7, a key competitive advantage as Dexcom moves to discontinue its legacy G6 system by July 2026.
Looking ahead, Dexcom expects to expand its profit margins significantly in 2026, targeting a non-GAAP operating margin of 22% to 23%.
This efficiency gain is being driven by the transition to more cost-effective sensor designs and the rollout of "Stelo," a new glucose-sensing platform tailored for the millions of people with Type 2 diabetes who do not use insulin.
The 2026 outlook factors in continued volume growth as the company pivots toward a broader metabolic health market.
Beyond traditional diabetes care, Dexcom is investing in AI-enabled software features—including personalized food logging and macronutrient insights—to maintain its premium positioning against intensifying competition from rivals like Abbott Laboratories.